Manufacturer profilePT. SENTRAL MEDIKA INDONESIA
IndonesiaIndonesia8 products registered
VerifiedKemenkes (Ministry of Health) · official registry
8
Total Products
8
Product Names
1
Product Classes
2
Risk Classes
Regulatory footprint
Search PT. SENTRAL MEDIKA INDONESIA across other regulatory registries
Thailand
European Union
Colombia
South Korea
Canada
EcuadorRisk classification breakdown
Distribution of products across risk classes
B337.5% of total
C562.5% of total
Product class portfolio
Products organized by product class
2
ONECARE Reagen Total Protein Mono, MEDIMAX Anti B Monoclonal, MEDIMAX Anti A Monoclonal, MEDIMAX Anti AB Monoclonal, MEDIMAX Anti D IgG/IgM Monoclonal ... and 3 more products in this class
8 Products
Recent registrations (8 most recent)
Most recently registered products with Ministry of Health
ONECARE Reagen Total Protein Mono
Dec 21, 2023
- Class
- 2
- Model
- -
- Risk Class
- B
MEDIMAX Anti B Monoclonal
Dec 20, 2023
- Class
- 2
- Model
- MX/AntiB00010
- Risk Class
- C
MEDIMAX Anti A Monoclonal
Dec 13, 2023
- Class
- 2
- Model
- MX/AntiA00010
- Risk Class
- C
MEDIMAX Anti AB Monoclonal
Dec 13, 2023
- Class
- 2
- Model
- MX/AntiAB0010
- Risk Class
- C
MEDIMAX Anti D IgG/IgM Monoclonal
Dec 13, 2023
- Class
- 2
- Model
- MX/AntiD00010
- Risk Class
- C
ONECARE Reagen Creatinine
Nov 28, 2023
- Class
- 2
- Model
- -
- Risk Class
- B
ONECARE Reagen Glucose Mono
Nov 21, 2023
- Class
- 2
- Model
- -
- Risk Class
- C
ONECARE Reagen Albumin
Nov 2, 2023
- Class
- 2
- Model
- -
- Risk Class
- B
About this profile
PT. SENTRAL MEDIKA INDONESIA from Indonesia is a medical device manufacturer with 8 registered products in the Indonesia Ministry of Health database through Pure Global AI's free platform. The company produces 8 unique product types across 1 product class.
This page provides comprehensive manufacturer intelligence including complete product portfolio, risk class distribution, and product class analysis. Pure Global AI offers free access to 67,600+ Indonesia medical device registrations, helping global MedTech companies identify manufacturers, analyze portfolios, and discover partnership opportunities efficiently.